Search
Semaglutide Treatment Options for Weight Loss
A collection of 71 research studies in Weight Loss where Semaglutide is the interventional treatment. Semaglutide is used for conditions such as Weight Loss.
37 - 48 of 71
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Weight Loss
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
GLP-1 Medications for Weight Loss Now Available!
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Semaglutide for Post-Smoking Cessation Weight Management
Recruiting
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/09/2024
Locations: The University of Texas at Austin, Austin, Texas +1 locations
Conditions: Obesity, Overweight, Cigarette Smoking
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Cahaba Research, Birmingham, Alabama +31 locations
Conditions: Obesity, Overweight
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss
Active Not Recruiting
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.
Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.
The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. Th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/21/2024
Locations: Pinnacle Research Group, Anniston, Alabama +58 locations
Conditions: Obesity
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Active Not Recruiting
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Gender:
ALL
Ages:
Between 65 years and 90 years
Trial Updated:
11/21/2024
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
Completed
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance.
Pa... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/10/2024
Locations: Baptist Health System, Montgomery, Alabama +65 locations
Conditions: Obesity
Prevention of Progression of Prediabetes, Obesity and CV Risk
Recruiting
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Latino Semaglutide Study
Completed
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/09/2024
Locations: Loma Linda University Health, Loma Linda, California
Conditions: Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
Active Not Recruiting
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/01/2024
Locations: ProSciento CRU, Chula Vista, California +6 locations
Conditions: Overweight and Obesity
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist
Completed
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg BID) or placebo for 5 days beginning on Day 1. On Day 2, all participants will receive a single subcutaneous injection of a GLP-1 agonist (semaglutide). Participants will remain at the clinical research unit for the duration of the treatment period.
The goal of this clinical trial is to evaluate the safety and efficacy of NG101 compared to placebo, when also administered along with a... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/23/2024
Locations: Celerion, Tempe, Arizona
Conditions: Overweight and Obesity, Healthy
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Completed
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: Diablo Clinical Research, Inc., Walnut Creek, California +13 locations
Conditions: Obesity
Semaglutide Use in Elderly Obese Patients
Active Not Recruiting
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/27/2024
Locations: Diabetes and Endocrinology Research Center, Buffalo, New York
Conditions: Obesity, Aging
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
Active Not Recruiting
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Gender:
ALL
Ages:
Between 60 years and 100 years
Trial Updated:
08/08/2024
Locations: Pinnacle Trials, Anniston, Alabama +13 locations
Conditions: Muscle Loss, Obesity
37 - 48 of 71